Near-100% immune response for new HIV vaccine candidate
Near-100% immune response for new HIV vaccine candidate
- The study, which has been supported by the HIV Vaccine Trials Network and the National Institutes of Health in the USA, tested the vaccine in combination with an immune activator, interleukin (IL)-12.
- The study, which has been supported by the HIV Vaccine Trials Network and the National Institutes of Health in the USA, tested the vaccine in combination with an immune activator, interleukin (IL)-12.
Chief executive Joseph Kim said: “These results are among
the highest ever responses we’ve seen with an HIV vaccine, and they are
remarkably consistent with our recent data reported from our Ebola, Zika
and MERS clinical trials in terms of demonstrating nearly 100% vaccine
response rates with very favorable safety profile.”